Get started
Biodesix, Inc.Biodesix, Inc.Biodesix, Inc.

Biodesix, Inc.

No trades
Buy BDSX
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

BDSX chart


Full chart

Upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪240.99 M‬USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.46USD
Net income (FY)
‪−52.15 M‬USD
Revenue (FY)
‪49.09 M‬USD
Shares float
‪76.49 M‬
Beta (1Y)
1.45

Employees


Employees (FY)
—
Revenue / Employee (1Y)
‪226.21 K‬USD
Net income / Employee (1Y)
‪−240.30 K‬USD

About Biodesix, Inc.


Sector
Health Services
Industry
Medical/Nursing Services
CEO
Scott Hutton
Website
biodesix.com
Headquarters
Louisville
Founded
2005
FIGI
BBG001J2LMV6
Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The firm offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It also offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. The company was founded by David Brunel and Robert E. Cawthorn in 2005 and is headquartered in Louisville, CO.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

Ideas



See all ideas 

News



Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Sparks


Curated watchlists where BDSX is featured.

See all sparks 

Frequently Asked Questions


The current price of BDSX is 1.70 USD — it has increased by 0.61% in the past 24 hours. Watch Biodesix, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Biodesix, Inc. stocks are traded under the ticker BDSX.
BDSX stock has risen by 6.25% compared to the previous week, the month change is a −4.60% fall, over the last year Biodesix, Inc. has showed a 18.06% increase.
We've gathered analysts' opinions on Biodesix, Inc. future price: according to them, BDSX price has a max estimate of 3.50 USD and a min estimate of 3.00 USD. Watch BDSX chart and read a more detailed Biodesix, Inc. stock forecast: see what analysts think of Biodesix, Inc. and suggest that you do with its stocks.
BDSX reached its all-time high on Jan 20, 2021 with the price of 31.99 USD, and its all-time low was 0.96 USD and was reached on Oct 27, 2022. View more price dynamics on BDSX chart.
See other stocks reaching their highest and lowest prices.
BDSX stock is 6.81% volatile and has beta coefficient of 1.45. Track Biodesix, Inc. stock price on the chart and check out the list of the most volatile stocks — is Biodesix, Inc. there?
Today Biodesix, Inc. has the market capitalization of ‪240.99 M‬, it has increased by 1.84% over the last week.
Yes, you can track Biodesix, Inc. financials in yearly and quarterly reports right on TradingView.
Biodesix, Inc. is going to release the next earnings report on Nov 1, 2024. Keep track of upcoming events with our Earnings Calendar.
BDSX earnings for the last quarter are −0.08 USD per share, whereas the estimation was −0.09 USD resulting in a 13.10% surprise. The estimated earnings for the next quarter are −0.07 USD per share. See more details about Biodesix, Inc. earnings.
Biodesix, Inc. revenue for the last quarter amounts to ‪17.90 M‬ USD, despite the estimated figure of ‪16.13 M‬ USD. In the next quarter, revenue is expected to reach ‪18.57 M‬ USD.
BDSX net income for the last quarter is ‪−10.81 M‬ USD, while the quarter before that showed ‪−13.61 M‬ USD of net income which accounts for 20.61% change. Track more Biodesix, Inc. financial stats to get the full picture.
No, BDSX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 1, 2024, the company has 217.00 employees. See our rating of the largest employees — is Biodesix, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Biodesix, Inc. EBITDA is ‪−27.96 M‬ USD, and current EBITDA margin is −72.91%. See more stats in Biodesix, Inc. financial statements.
Like other stocks, BDSX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Biodesix, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Biodesix, Inc. technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Biodesix, Inc. stock shows the buy signal. See more of Biodesix, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.